Acino signs an exclusive distribution agreement with the Swedish biopharmaceutical company Sobi in Kazakhstan
The agreement focuses on the distribution of orphan drugs developed for patients with conditions such as rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, Still’s disease, paroxysmal nocturnal hemoglobinuria, type 1 tyrosinemia, thrombocytopenia, primary hemophagocytic lymph histiocytosis, and chylomicronemia syndrome.
ZURICH, Switzerland, 29 January 2024 – Acino, a Swiss pharmaceutical company, today announced that it has signed an exclusive distribution agreement with Sobi, a Swedish biopharmaceutical company, for the commercialisation of several orphan drugs: Doptelet®, Aspaveli®, Gamifant®, Kineret®, Orfadin®, Tegsedi®, Waylivra® in Kazakhstan. Under the terms of this five-year agreement, Acino will market and commercialise Sobi’s products in the specialised hospital segment as of the beginning of 2024.
“Acino is committed to providing access to essential therapies for patients with rare diseases in the emerging markets. This agreement with Sobi further strengthens our presence in Kazakhstan and neighbouring countries, where we have established ourselves as a trusted manufacturer and leading supplier of high-quality innovative drugs,” said Eugene Zaika, Head of the Ukraine and CIS Region at Acino.
Acino occupies about 30% of the target market segment and ranks among the top 20 pharmaceutical companies in Kazakhstan across key therapeutic areas including oncology, cardiology, neurology, gynecology, and endocrinology.*
Collaboration with Acino will enable Sobi to reach more patients in underserved areas, ensuring more people in urgent need will have access to innovative medicines.
”This partnership aligns with Sobi’s mission to transform the lives of people with rare and debilitating diseases, expanding access to treatments for those who need them the most. Together, we hope to make a meaningful difference in the lives of patients in Kazakhstan,” stated Konstantin Bakaykin, Vice President, General Manager of CEER & Japan.
*According to IQVIA report
-ENDS-
About Acino
Acino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, Ukraine, the CIS Region, and Latin America. Acino is part of ADQ, an Abu Dhabi based investment and holding company. We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing.
About Sobi
Sobi is a specialized international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of hematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East and Asia. In 2022, revenue amounted to SEK 18.8 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.